The goal of this clinical research study is to learn if RAD001 can shrink or slow the growth
of tumors in patients who have recurrent endometrial cancer. The safety of this drug will
also be studied.
Objectives:
Primary Objective:
1. To determine the efficacy of RAD001 in patients with progressive or recurrent endometrial
cancer.
Secondary Objective:
1. To determine the nature and degree of toxicity of RAD001 in this cohort of patients.
2. To characterize, in pre- and post- treatment tumor samples, when available, expression
levels of total and phosphorylated mTOR (mammalian "target of rapamycin") as well as
relevant upstream and downstream signaling components (optional).